L’Arboç, Spain — October 4th, 2024 – invoX Pharma Limited (“invoX”), a research-driven global biopharmaceutical company, has entered into a new strategic collaboration with H&T Presspart (a division of the Heitkamp & Thumann Group), a leading contract developer and manufacturer of drug delivery components and devices.

Through this collaboration, H&T Presspart will manufacture the device sub-assembly for the commercialisation of invoX’s complex soft mist inhalation (SMI) device, the Softhaler®. As invoX’s designated industrialisation and manufacturing partner, H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain.

The Softhaler® is a next-generation, proprietary soft-mist inhalation platform device, which uses differentiated technology to deliver propellant-free liquid-based formulations to the lung. It is a purely mechanical device that uses water-based formulations and contains no propellants. The Softhaler® device mechanically converts the liquid formulation into an ultra-fine mist to deliver the medication to the lungs more effectively, leading to better lung delivery and less deposition in the mouth or at the back of the throat.

invoX Pharma has a number of agreements in place for the development and commercialisation of generic and innovative drug-device combination products using the Softhaler®.

“We are excited about working with an expert in the field of medical device component manufacture and device assembly,” said Ben Toogood, Chief Executive Officer at invoX. “This partnership will deliver commercial scale manufacturing capability for our device, which is a key step in working with our development partners to bring the Softhaler to market. We are focused on bringing the Softhaler to patients with respiratory diseases, so that they can benefit from medications delivered through our next-generation device.”

Christian Krätzig, President H&T Presspart commented, “This partnership underlines our strategic commitment to support customers in the commercialisation of highly complex drug-device combination products. As a leading developer and manufacturer of drug delivery devices and our expertise in the inhalation market, we are thrilled to be partnering with invoX to bring next generation SMIs to patients worldwide.”

About invoX Pharma

invoX Pharma is a research-driven global biopharmaceutical company using next-generation technology platforms to discover and develop innovative medicines that can change the lives of people around the world. The company aspires to improve people’s lives by creating access to innovative medicines that address their unmet healthcare needs. Incorporated in March 2021, invoX has a core focus on oncology and respiratory therapeutics, with Research, Clinical Development and Business Development activities in the UK, EU, and US. For further information about invoX Pharma, please visit: https://invoxpharma.com/

About H&T Presspart

H&T Presspart is a market leading developer and manufacturer of drug delivery devices and components with more than 50 years’ experience and enjoys a worldwide reputation for competence, quality, and innovation in the pharmaceutical market. With a wide portfolio of components, device solutions and services, H&T Presspart partners to deliver exceptional

customer experience and accelerated routes to market of customers’ drug-device programs. H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland, and the UK and has sales representation in China, India, the U.S.A., and Uruguay. For more information, please visit www.presspart.com.